Literature DB >> 25681658

HIF targets in bone remodeling and metastatic disease.

Rachelle W Johnson1, Ernestina Schipani2, Amato J Giaccia3.   

Abstract

The bone marrow is a hypoxic microenvironment that is rich in growth factors and blood vessels and is readily colonized by tumor cells disseminated from numerous cancers including tumors of the breast, prostate, lung, and skin. The origin of metastatic growth promoting factors for tumor cells disseminated to the bone marrow is derived from multiple sources: the bone matrix, which is a reservoir for growth factors, and cells residing in the marrow and along bone surfaces, such as osteoblasts, osteoclasts, macrophages, and T cells, which secrete cytokines and chemokines. Low oxygen levels within the bone marrow induce hypoxia signaling pathways such as hypoxia inducible factor (HIF), which is regulated by oxygen requiring prolyl hydroxylases (PHDs) and von Hippel-Lindau (VHL) tumor suppressor. These hypoxia signaling pathways have profound effects on bone development and homeostasis. Likewise, hypoxic conditions observed in local breast and prostate tumors point to a role for hypoxia-inducible genes in metastasis to and colonization of the bone marrow. This review will explore the role of hypoxia-regulated factors in bone development and remodeling, and how these elements may contribute to solid tumor metastasis to the bone.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone metastasis; Bone microenvironment; HIF; Hypoxia; PHD; Remodeling

Mesh:

Substances:

Year:  2015        PMID: 25681658      PMCID: PMC4414805          DOI: 10.1016/j.pharmthera.2015.02.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  123 in total

1.  Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer.

Authors:  Noel W Clarke
Journal:  Eur Urol       Date:  2013-07-26       Impact factor: 20.096

2.  Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.

Authors:  A Poprach; T Pavlik; B Melichar; I Puzanov; L Dusek; Z Bortlicek; R Vyzula; J Abrahamova; T Buchler
Journal:  Ann Oncol       Date:  2012-06-13       Impact factor: 32.976

3.  Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Authors:  Seong Joon Park; Jae-Lyun Lee; Inkeun Park; Kwonoh Park; Yongcheol Ahn; Jin-Hee Ahn; Dae-Ho Lee; Shin Ahn; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  Chemotherapy       Date:  2013-03-20       Impact factor: 2.544

Review 4.  Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Authors:  Benjamin A Gartrell; Robert E Coleman; Karim Fizazi; Kurt Miller; Fred Saad; Cora N Sternberg; Matthew D Galsky
Journal:  Eur Urol       Date:  2013-05-13       Impact factor: 20.096

5.  Long-term response to sunitinib therapy for metastatic renal cell carcinoma.

Authors:  Ana M Molina; Xiaoyu Jia; Darren R Feldman; James J Hsieh; Michelle S Ginsberg; Susanne Velasco; Sujata Patil; Robert J Motzer
Journal:  Clin Genitourin Cancer       Date:  2013-05-24       Impact factor: 2.872

6.  Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.

Authors:  Bruno Neri; Agnese Vannini; Marco Brugia; Andrea Muto; Sheila Rangan; Mattia Rediti; Renato Tassi; Carmine Cerullo
Journal:  Int J Urol       Date:  2012-11-01       Impact factor: 3.369

7.  A retrospective study of incidence of bone metastasis in head and neck cancer.

Authors:  Virendra Bhandari; Ravi Kant Jain
Journal:  J Cancer Res Ther       Date:  2013 Jan-Mar       Impact factor: 1.805

8.  Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

Authors:  Daniele Santini; Giuseppe Procopio; Camillo Porta; Toni Ibrahim; Sandro Barni; Calogero Mazzara; Andrea Fontana; Alfredo Berruti; Rossana Berardi; Bruno Vincenzi; Cinzia Ortega; Davide Ottaviani; Giacomo Carteni; Gaetano Lanzetta; Vladimir Virzì; Matteo Santoni; Nicola Silvestris; Maria Antonietta Satolli; Elena Collovà; Antonio Russo; Giuseppe Badalamenti; Stefano Luzi Fedeli; Francesca Maria Tanca; Vincenzo Adamo; Evaristo Maiello; Roberto Sabbatini; Alessandra Felici; Saverio Cinieri; Giuseppe Tonini; Sergio Bracarda
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

9.  Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.

Authors:  Nobuyuki Katakami; Hiroshi Kunikane; Koji Takeda; Koichi Takayama; Toshiyuki Sawa; Hiroshi Saito; Masao Harada; Soichiro Yokota; Kiyoshi Ando; Yuko Saito; Isao Yokota; Yasuo Ohashi; Kenji Eguchi
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

10.  Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Bruno Vincenzi; Andrea Napolitano; Alice Zoccoli; Michele Iuliani; Francesco Pantano; Nicola Papapietro; Vincenzo Denaro; Daniele Santini; Giuseppe Tonini
Journal:  J Hematol Oncol       Date:  2012-09-17       Impact factor: 17.388

View more
  25 in total

Review 1.  Mechanistic role of perfusion culture on bone regeneration.

Authors:  Bhaskar Birru; Naveen Kumar Mekala; Sreenivasa Rao Parcha
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

2.  Tumor dormancy in bone.

Authors:  Vera Mayhew; Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-29

Review 3.  Breast Cancer Dormancy in Bone.

Authors:  Miranda E Clements; Rachelle W Johnson
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

Review 4.  Hallmarks of Bone Metastasis.

Authors:  Rachelle W Johnson; Larry J Suva
Journal:  Calcif Tissue Int       Date:  2017-11-14       Impact factor: 4.333

5.  Sema4D expression and secretion are increased by HIF-1α and inhibit osteogenesis in bone metastases of lung cancer.

Authors:  Wu-Gui Chen; Jing Sun; Wei-Wei Shen; Si-Zhen Yang; Ying Zhang; Xu Hu; Hao Qiu; Shang-Cheng Xu; Tong-Wei Chu
Journal:  Clin Exp Metastasis       Date:  2019-01-07       Impact factor: 5.150

Review 6.  Hypoxia: Signaling the Metastatic Cascade.

Authors:  Erinn B Rankin; Jin-Min Nam; Amato J Giaccia
Journal:  Trends Cancer       Date:  2016-06-02

Review 7.  Engineering 3D Models of Tumors and Bone to Understand Tumor-Induced Bone Disease and Improve Treatments.

Authors:  Kristin A Kwakwa; Joseph P Vanderburgh; Scott A Guelcher; Julie A Sterling
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

8.  Differential expression of genes associated with hypoxia pathway on bone marrow stem cells in osteoporosis patients with different bone mass index.

Authors:  Qi Zhu; Chang Shan; Ling Li; Lige Song; Keqin Zhang; Yun Zhou
Journal:  Ann Transl Med       Date:  2019-07

Review 9.  Targeting Histone Modifications in Bone and Lung Metastatic Cancers.

Authors:  Courtney M Edwards; Rachelle W Johnson
Journal:  Curr Osteoporos Rep       Date:  2021-03-15       Impact factor: 5.163

Review 10.  Cell and Signal Components of the Microenvironment of Bone Metastasis Are Affected by Hypoxia.

Authors:  Paola Bendinelli; Paola Maroni; Emanuela Matteucci; Maria Alfonsina Desiderio
Journal:  Int J Mol Sci       Date:  2016-05-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.